325 related articles for article (PubMed ID: 33141168)
1. An miRNA signature associated with tumor mutation burden in endometrial cancer.
Zhou H; Chen L; Qin M; Lei Y; Li T; Li H; Cheng X
Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33141168
[TBL] [Abstract][Full Text] [Related]
2. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
Front Immunol; 2021; 12():788431. PubMed ID: 34970268
[TBL] [Abstract][Full Text] [Related]
3. Integrated analysis of tumor mutation burden and immune infiltrates in endometrial cancer.
Zhou H; Chen L; Lei Y; Li T; Li H; Cheng X
Curr Probl Cancer; 2021 Apr; 45(2):100660. PubMed ID: 33012523
[TBL] [Abstract][Full Text] [Related]
4. MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer.
Lu N; Liu J; Ji C; Wang Y; Wu Z; Yuan S; Xing Y; Diao F
Bioengineered; 2021 Dec; 12(1):3603-3620. PubMed ID: 34252354
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of a miRNA-related expression signature for tumor mutational burden in colorectal cancer.
Xu L; Zheng Q
World J Surg Oncol; 2021 Feb; 19(1):56. PubMed ID: 33610190
[TBL] [Abstract][Full Text] [Related]
6. MiRNA expression patterns are associated with tumor mutational burden in lung adenocarcinoma.
Lv Y; Huang Z; Lin Y; Fang Y; Chen Z; Pan L; Zhang Y; Xu Z
Oncoimmunology; 2019; 8(10):e1629260. PubMed ID: 31646073
[No Abstract] [Full Text] [Related]
7. miRNA-Based Feature Classifier Is Associated with Tumor Mutational Burden in Head and Neck Squamous Cell Carcinoma.
Xia Y; Wang Q; Huang X; Yin X; Song J; Ke Z; Duan X
Biomed Res Int; 2020; 2020():1686480. PubMed ID: 33490233
[TBL] [Abstract][Full Text] [Related]
8. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
Front Immunol; 2021; 12():693062. PubMed ID: 34497605
[TBL] [Abstract][Full Text] [Related]
9. Identification of a Multi-RNA-Type-Based Signature for Recurrence-Free Survival Prediction in Patients with Uterine Corpus Endometrial Carcinoma.
Wang P; Zeng Z; Shen X; Tian X; Ye Q
DNA Cell Biol; 2020 Apr; 39(4):615-630. PubMed ID: 32105510
[TBL] [Abstract][Full Text] [Related]
10. A Five-microRNA Signature as Risk Stratification System in Uterine Corpus Endometrial Carcinoma.
Chen Z; Huang X; Lv Y; Fang Y; Pan L; Gan Z; Huang Z; Wei W
Comb Chem High Throughput Screen; 2021; 24(2):187-194. PubMed ID: 32748742
[TBL] [Abstract][Full Text] [Related]
11. MiRNA-based model for predicting the TMB level in colon adenocarcinoma based on a LASSO logistic regression method.
Li Z; Jiang L; Zhao R; Huang J; Yang W; Wen Z; Zhang B; Du G
Medicine (Baltimore); 2021 May; 100(21):e26068. PubMed ID: 34032736
[TBL] [Abstract][Full Text] [Related]
12. miRNA-Based Signature Associated With Tumor Mutational Burden in Colon Adenocarcinoma.
Xue W; Wang Y; Xie Y; Yang C; Gong Z; Guan C; Wei C; Zhu C; Niu Z
Front Oncol; 2021; 11():634841. PubMed ID: 34262855
[TBL] [Abstract][Full Text] [Related]
13. Protein-based prognostic signature for predicting the survival and immunotherapeutic efficiency of endometrial carcinoma.
Lai J; Xu T; Yang H
BMC Cancer; 2022 Mar; 22(1):325. PubMed ID: 35337291
[TBL] [Abstract][Full Text] [Related]
14. MicroRNAs Expression Patterns Predict Tumor Mutational Burden in Colorectal Cancer.
Huang J; Liu H; Zhao Y; Luo T; Liu J; Liu J; Pan X; Tang W
Front Oncol; 2020; 10():550986. PubMed ID: 33634010
[TBL] [Abstract][Full Text] [Related]
15. A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.
Tian Y; Xu J; Chu Q; Duan J; Zhang J; Bai H; Yang Z; Fang W; Cai L; Wan R; Fei K; He J; Gao S; Zhang L; Wang Z; Wang J
BMC Med; 2020 Aug; 18(1):232. PubMed ID: 32843031
[TBL] [Abstract][Full Text] [Related]
16. Can Endometrial Cytology Identify Patients Who Would Benefit from Immunotherapy?
Yanazume S; Kirita Y; Kobayashi Y; Kitazono I; Akahane T; Mizuno M; Togami S; Tanimoto A; Kobayashi H
Acta Cytol; 2024; 68(2):128-136. PubMed ID: 38471464
[TBL] [Abstract][Full Text] [Related]
17. A four-miRNA signature as a novel biomarker for predicting survival in endometrial cancer.
Wu YS; Lin H; Chen D; Yi Z; Zeng B; Jiang Y; Ren G
Gene; 2019 May; 697():86-93. PubMed ID: 30779946
[TBL] [Abstract][Full Text] [Related]
18. Development of a 4-miRNA prognostic signature for endometrial cancer.
Huang J; Du F; Wang N
Medicine (Baltimore); 2022 Oct; 101(41):e30974. PubMed ID: 36254064
[TBL] [Abstract][Full Text] [Related]
19. Mining The Cancer Genome Atlas database for tumor mutation burden and its clinical implications in gastric cancer.
Zhao DY; Sun XZ; Yao SK
World J Gastrointest Oncol; 2021 Jan; 13(1):37-57. PubMed ID: 33510848
[TBL] [Abstract][Full Text] [Related]
20. Identification of a six-gene signature with prognostic value for patients with endometrial carcinoma.
Wang Y; Ren F; Chen P; Liu S; Song Z; Ma X
Cancer Med; 2018 Nov; 7(11):5632-5642. PubMed ID: 30306731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
